Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

a and an established global regulatory and commercial

organization.

-- Sales of Aldurazyme(R) (laronidase) increased 38 percent to $37.0

million in the first quarter, compared with $26.8 million in the same

quarter a year ago. Genzyme now records sales of Aldurazyme on its top

line and makes tiered payments to BioMarin Pharmaceutical Inc. on

worldwide product sales under a restructured agreement between the

companies.

-- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent

in the first quarter to $33.8 million from $26.3 million, reflecting

ongoing improvement in thyroid cancer detection and well-established

treatment guidelines. The use of Thyrogen in ablation procedures is

also contributing to the product's growth, following the December 2007

U.S. approval for this indication.

-- Within the Renal business, sales of sevelamer therapies Renagel(R)

(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million

from $137.4 million in the first quarter last year. In March, Genzyme

launched Renvela in the United States, where the company is engaged in

active discussions with the FDA to expand the product's labeling to

include chronic kidney disease patients with hyperphosphatemia who are

not on dialysis. The three companies that currently market phosphate

binders are working collaboratively to provide the FDA with information

that will help the agency determine the appropriate treatment paradigm

for these patients. Genzyme anticipates that the Renvela label

expansion will take place at the latest by the middle of 2009. Genzyme

has also filed for European approval for Renvela in both the dialysis

and chronic kidney disease indications.

-- Within the Transplant business, first-quarter sales of Thymoglobulin(R)
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Reiterates $3.00 per Share Proposal is Best and Final ... Company,(NYSE: LLY ) today reaffirmed that its $3.00 ... SGXP ) represents its best and final offer,for the ... two,companies announced the signing of a definitive merger agreement, ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company focused ... in the areas of women,s health and,cancer, announced today ... presenting at the BMO Capital Markets 2008 Focus on ... begin at 2:15 PM,ET on Tuesday, August 5, 2008 ...
... to Monitor Activity of New ... Class of Potent Antiretroviral Drugs, SOUTH SAN ... ) today announced the launch of its,PhenoSense(R) Integrase assay, built ... susceptibility of,HIV to a new and potent class of integrase ...
Cached Biology Technology:Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 3Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 4Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 5
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... scientist, has just solved the structure of the first mammalian ... and certain cancers. His work is being published today ... Molecular Cell. Gewirths study confirms his 2001 ... same family as the better known HSP90 proteins. As ...
... Spring Harbor, NY Gregory J. Hannon, Ph.D., ... Hughes Medical Institute (HHMI) investigator, along with two ... the Memorial Sloan-Kettering Cancer Centers (MSKCC) 2007 Paul ... named after Paul A. Marks, Ph.D., President Emeritus ...
... researchers have shown that nanodiamonds -- much like the ... diamond but on a much smaller scale -- are ... the negative effects associated with current drug delivery agents. ... Letters, is the first to demonstrate the use of ...
Cached Biology News:First high-res 3D structures of mammalian HSP90 protein solved 2First high-res 3D structures of mammalian HSP90 protein solved 3Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2Nanoengineers mine tiny diamonds for drug delivery 2Nanoengineers mine tiny diamonds for drug delivery 3Nanoengineers mine tiny diamonds for drug delivery 4
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
...
...
Biology Products: